5% Albumin

DRUG5 trials

Sponsors

Fresenius Kabi, Vanderbilt University Medical Center, Ottawa Hospital Research Institute, Yonsei University, Institute of Liver and Biliary Sciences, India

Conditions

Cardiac DiseasesCoronary Artery Occlusive Disease(CAOD)Intraoperative ComplicationsLiver CirrhosisSepsisSeptic ShockSevere Sepsis

Phase 2

Fluid Resuscitation in Early Septic Shock

CompletedNCT00819416

Ottawa Hospital Research InstituteSepsis, Septic Shock, Severe Sepsis

Start: 2009-02-28End: 2010-02-28Updated: 2010-04-14

Phase 4

Hydroxyethyl Starch (130/0.4) for Intravascular Volume Therapy in Liver Transplantation

TerminatedNCT00308100

Fresenius KabiIntraoperative Complications

Start: 2005-10-31End: 2008-07-31Updated: 2009-01-15

The Effect of Balanced Crystalloid Versus 5% Albumin on Endothelial Glycocalyx Degradation in Patients Undergoing Off-pump Coronary Artery Bypass Surgery

CompletedNCT03699462

Yonsei UniversityCoronary Artery Occlusive Disease(CAOD)

Start: 2018-11-13End: 2020-10-17Updated: 2020-11-02

Unknown Phase

The Use of Colloid Versus Crystalloid in Post-operative Pediatric Cardiac Patients for Fluid Resuscitation

CompletedNCT00464126

Vanderbilt University Medical CenterCardiac Diseases

Start: 2006-08-31End: 2009-07-31Updated: 2017-04-04

Efficacy of 5% Albumin v/s Plasmalyte in Combination With 20% Albumin for Fluid Resuscitation in Cirrhosis With Sepsis Induced Hypotension

Institute of Liver and Biliary Sciences, IndiaLiver Cirrhosis

Start: 2023-09-30End: 2024-08-31Target: 120Updated: 2023-10-10

Related Papers

Effect of 5% albumin on endothelial glycocalyx degradation during off-pump coronary artery bypass.

2023-11-21